Etoricoxib + Paracetamol in pharma franchise in Kolkata

Etoricoxib + Paracetamol in PCD pharma franchise in Bihar

Etoricoxib + Paracetamol in top pharma company in Delhi

Etoricoxib + Paracetamol in pcd pharma supplier in Raipur

Etoricoxib + Paracetamol in phama franchise company in India
Etoricoxib + Paracetamol in phama distributor in Vellore

Home/Products /etoricoxib-60mg-paracetamol-325mg-tablet

Etoscrib P Tablet

Composition : Etoricoxib (60mg) + Paracetamol (325mg)

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10x10

Price : ₹158/-

Etoscrib P Tablet combines two active ingredients: Etoricoxib (60 mg) and Paracetamol (325 mg). This formulation is designed to provide effective relief from moderate to severe pain, making it particularly useful for conditions such as osteoarthritis, rheumatoid arthritis, and acute pain episodes. By targeting pain through dual mechanisms, Etoscrib P Tablet helps improve mobility and quality of life for individuals experiencing discomfort from inflammatory or musculoskeletal conditions.

Etoricoxib is a selective COX-2 inhibitor that reduces inflammation and alleviates pain while minimizing gastrointestinal side effects commonly associated with traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Paracetamol complements this action by providing additional pain relief and reducing fever. This combination allows for a synergistic effect, ensuring that patients experience effective relief without the risk of increased gastrointestinal complications.

Read More

About the Product

Etoscrib P Tablet combines two active ingredients: Etoricoxib (60 mg) and Paracetamol (325 mg). This formulation is designed to provide effective relief from moderate to severe pain, making it particularly useful for conditions such as osteoarthritis, rheumatoid arthritis, and acute pain episodes. By targeting pain through dual mechanisms, Etoscrib P Tablet helps improve mobility and quality of life for individuals experiencing discomfort from inflammatory or musculoskeletal conditions.

Etoricoxib is a selective COX-2 inhibitor that reduces inflammation and alleviates pain while minimizing gastrointestinal side effects commonly associated with traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Paracetamol complements this action by providing additional pain relief and reducing fever. This combination allows for a synergistic effect, ensuring that patients experience effective relief without the risk of increased gastrointestinal complications.

Potential side effects may include nausea, dizziness, headache, and gastrointestinal disturbances. In rare cases, serious allergic reactions or cardiovascular events may occur.

Etoscrib P Tablet is indicated for the management of moderate to severe pain, including pain associated with arthritis and acute pain episodes.

Consult a healthcare professional before use, especially if you have a history of heart disease, liver dysfunction, or gastrointestinal issues. In conclusion, Etoscrib P Tablet offers a robust solution for pain management by combining the analgesic properties of Paracetamol with the anti-inflammatory benefits of Etoricoxib. This unique formulation not only targets pain effectively but also prioritizes patient safety by reducing the likelihood of common NSAID-related side effects. Always follow prescribed dosages and consult with a healthcare provider for any concerns regarding this medication.

Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation